|
|
|

 |
|
1232
22nd Street N.W.
Washington, D.C.
20037-1202
(202) 223.2226
1 (800) 231.4222 |
|
|
|
 |
8th
ISO |
|
Symposium Purpose
The National Osteoporosis Foundation (NOF)-sponsored International Symposium on Osteoporosis (ISO) is designed to provide the most current and clinically relevant evidence-based information on the prevention, diagnosis, and treatment of osteoporosis. This will be accomplished through in-depth educational sessions addressing primary and secondary osteoporosis, clinical considerations and therapeutics, socio-behavioral medicine, nutrition, education, epidemiology, pathophysiology, genetics and emerging science.
In the U.S. today, ten million individuals already have osteoporosis and 34 million more have low bone mass, placing them at increased risk for the disease and related fractures. One in two women and one in four men age 50 and older are at risk for an osteoporosis-related fracture in their lifetime. The disease affects people of all ethnic backgrounds.
Increased life expectancy puts greater numbers at risk for osteoporosis, the need for early and accurate diagnosis becomes more critical. While osteoporosis can be reliably diagnosed, treated and prevented if often goes undetected in patients, leading to severe physical, social, functional and psychological consequences including increased mortality and morbidity.
Thus, improving the diagnosis and treatment of osteoporosis is a major challenge and priority for healthcare professionals. The programs that comprise the 8th International Symposium stress the practical application of science and research to the clinical management of patients with osteoporosis and low bone mass.
Overall Outcome Objectives
After participating in this International Symposium on Osteoporosis participants should be able to:
- Appreciate the significant threat of osteoporosis through the latest epidemiology of the disease
- Comprehend the physiology and genetics of osteoporosis in order to improve diagnosis and treatment
- Perform appropriate clinical assessments to determine potential presence
of secondary osteoporosis
- Determine treatment options that consider both the secondary conditions and the osteoporosis
- Apply clinical decision-making tools for osteoporosis management within the medical practice environment
- Differentiate among FDA-approved medications and select appropriate therapies as indicated
- Utilize primary, secondary and tertiary treatment modalities for osteoporosis across the continuum of care
- Develop patient and consumer education programs within their practice
and community
- Take advantage of available resources that can impact bone health and
quality of life
- Comprehend emerging discoveries and their affect on the future of
osteoporosis care
Target
Audience
This scientific program is designed for healthcare professionals with an interest in osteoporosis and bone health across the lifespan, including those working in family practice, endocrinology, rheumatology, obstetrics/gynecology, radiology, physical and occupational therapy and research.
These include:
- Physicians
- Nurses
- Nurse Practitioners
- Physician Assistants
|
- Dietetians
- Radiology Technicians
- Physical and Occupational Therapists
- Pharmacists
|
Preliminary Program (as of February 2009)
Wednesday, April 1, 2009 |
2:00 p.m. |
Hands on Workshops
Using Fracture Risk Assessment in Your Practice, Marjorie Luckey, MD
Pharmacological Treatments for Osteoporosis: Past, Present and Future, E. Michael Lewiecki, MD |
Thursday, April 2, 2009 |
8:00 a.m. |
Lessons from Space Travel for Improving Bone Health on Earth, Peter Cavanagh, PhD |
9:30 a.m. |
Poster Presentations and Exhibit Hall Break |
10:30 a.m. |
Plenary
Osteoporosis: Secondary Causes of Bone Loss
Determining Secondary Causes of Osteoporosis, Marjorie Luckey, MD
Thyroid Disease and Bone Loss, David Cooper, MD
Chronic Kidney Disease and Bone Health, Paul Miller, MD |
1:15 p.m. |
Plenary
Identification and Management of Osteoporosis: Maximizing the Utility of DXA and Risk Factors
Use of Biochemical Markers in Osteoporosis Management, Michael Kleerekoper, MD
Interpreting the DXA Report and Vertebral Fracture Assessment, E. Michael Lewiecki, MD
Utilizing Risk Factors in Assessing Fracture Risk and Targeting Treatment,
Ethel Siris, MD |
3:00 p.m. |
Concurrent Sessions
Premenopausal Skeletal Development
Prenatal and Early Postnatal Skeletal Development, Winston Koo, MD
Adolescent Skeleton, Catherine Gordon, MD
Relationships between Birth Control, Depo Provera, Pregnancy, Lactation and Bone Health, MaryFran Sowers, MD
Osteoporosis in Men
Diagnosis, Treatment, Risk Factors and the NOF Clinical Guidelines for Men with Osteoporosis, Eric Orwoll, MD
Male Spinal Cord Injury and Bone, Robert Adler, MD
Determinants of Initiation and Continuation of Antiresorptive Therapy
Role of Primary Care for Osteoporosis Management, Vernon J. Hershberger, MD
How and How Long to Treat Osteoporosis, Juliet Compston, MD
The Positive Role of Exercise in Good Posture, Safe Body Mechanics, and Return to Function After Fracture
Posture and Body Mechanics, Carleen Lindsey, PT
Exercise to Return to Function After Vertebral Fracture, Kathy Shipp, PT
Post Hip Fracture Care, Jay Magaziner, PhD
New Concepts in the Physiology of Skeletal Health
Pathogenetic Mechanisms in Bone Loss, Lawrence Raisz, MD
Genetics of Bone, Joseph Zmuda, PhD |
Friday, April 3, 2009 |
8:00 a.m. |
Plenary
Osteoporosis: Diseases and Bone Loss
Osteoporosis and the Bowel: What’s the Link?, Peter Green, MD
Renal Calculi, Hypercalcemia and Hypercalciuria, Murray Favus, MD
Weight Loss, Bariatric Surgery and Bone, Jeffrey Mechanick, MD
Eating Disorders and Bone Loss, Madhu Misra, MD |
9:45 a.m. |
Poster Presentations and Exhibit Hall Break |
10:45 a.m. |
Meet the Professor Sessions
Premenopausal Women, Elizabeth Shane, MD
Kyphoplasty and Vertebroplasty, Mary E. Jensen, MD
Fundamentals and Pitfalls of DXA Interpreting: Physician and Technologist Interactive Session, Nelson Watts, MD and JoAnn Caudill, RT
Patient and Professional Education in Osteoporosis, Daniel Solomon, MD
Nutrition and Osteoporosis, Connie Weaver, PhD |
1:00 p.m. |
Plenary
Non-Pharmacological Issues in Osteoporosis Management I
Calcium and Vitamin D, Bess Dawson-Hughes, MD
Exercise Prescription for Osteoporosis, Karen Kemmis, DPT
Osteoporosis Treatments: Compliance and Persistence, Deborah T. Gold, PhD
Nutraceuticals: Effects on Bone Metabolism, Jeri Nieves, PhD |
2:45 p.m. |
Plenary
Osteoporosis: Medication, Disease and Bone Loss
Cancer Therapy-Induced Bone Loss in Women, Robert Gagel, MD
Cancer Therapy-Induced Bone Loss in Men, Susan Greenspan, MD
Glucocorticoid-Induced Bone Loss, Kenneth Saag, MD
PPIs, Anticoagulants and Antiseizure Medications and Bone Loss, Mary Beth O’Connell, PharmD |
4:30 p.m. |
Plenary
Coalition for a National Action Plan on Bone Health: Bone Summit Panel Discussion
Panelists:
Leo Schargorodski
Joan McGowan, PhD
Robert Gagel, MD |
Saturday, April 4, 2009 |
8:00 a.m. |
Plenary
Disease and Therapy-Induced Bone Loss
Diabetes and Its Treatment: Outcomes for Bone, John Bilezikian, MD
Stroke, Parkinson’s Disease and Bone Health, F. Michael Gloth III, MD
Depression and Bone, Jonathan D. Adachi, MD
Rheumatoid Arthritis and Connective Tissue Disease: Their Impact on Bone, Chad Deal, MD |
9:45 a.m. |
Poster Presentations and Exhibit Hall Break |
10:45 a.m. |
Meet the Professor Sessions
Premenopausal Women, Elizabeth Shane, MD
Kyphoplasty and Vertebroplasty, Mary E. Jensen, MD
Fundamentals and Pitfalls of DXA Interpreting: Physician and Technologist Interactive Session, Nelson Watts, MD and JoAnn Caudill, RT
Low Peak Bone Mass: When is it Real and When a Fiction?, Robert Lindsay, MD, PhD
Nutrition and Osteoporosis, Connie Weaver, PhD |
|
Plenary
Non-Pharmacological Issues in Osteoporosis Management II
Fall Prevention, Stephanie Studenski, MD
Osteoporosis in the Long Term Care Setting, Douglas Kiel, MD
Osteoporosis and Its Effect on Quality of Life, Stuart Silverman, MD |
2:45 p.m. |
Case Studies
Early Postmenopausal Women and Bone, Margery Gass, MD
Role of Advanced Practice Clinicians (NPs and PAs) in Prevention and Identification of Osteoporosis, Adrienne Berarducci, PhD, ARNP and Rick Pope, PA-C
Subtrochanteric and Stress Fractures, Joseph Lane, MD |
Sunday, April 5, 2009 |
8:00 a.m. |
Plenary
FDA-Approved Therapies for Osteoporosis
Bisphosphonates for Osteoporosis: Current Uses and Challenges, Steven Harris, MD
Anabolic Therapy for Osteoporosis, Felicia Cosman, MD
Hormonal Therapies for Osteoporosis: Estrogen, Calcitonin and EEAs (SERMs), Robert Lindsay, MD, PhD
Treatment of Osteoporosis in the Setting of Hypogonadism: Use of Testosterone and Other Agents, Benjamin Leder, MD |
10:15 a.m. |
Plenary
Emerging Therapies and Diagnostic Techniques
Bone Quality: New Imaging to Refine Fracture Risk and Improve Therapy,
Mary Bouxsein, PhD and David Dempster, PhD
Emerging Pharmaceutical Therapies: Denosumab and New EEAs, Michael McClung, MD |
Continuing Education
The 8th International Symposium on Osteoporosis: Translating Research into Clinical Practice has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).
Physicians: The National Osteoporosis Foundation designates this educational activity for a maximum of 26.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians Assistants: This program has been reviewed and is approved for a maximum of 26.5 hours of AAPA Category I CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Live Programs and for Commercial Support of Live Programs.
Nurses: This continuing nursing education activity was approved by the Virginia Nurses' Association Continuing Education Approval Committee, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.)
Nurse Practitioners: This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 26.5 contact hours of continuing education credit including 13.0 hours of pharmacology credit. NPWH Activity number 09-02.
Each participant should claim only those contact hours that he/she actually spent in the educational activity.
Other Healthcare Professionals: Certificates of Completion will be provided to all other participants seeking continuing education credit from their specific accrediting organizations. Many accrediting organizations recognize the approval of ACCME PRA Category 1 credit; please note this activity has this type of approval.
Disclosure Policies
It is the policy of the National Osteoporosis Foundation to ensure balance, independence, objectivity, and scientific rigor in all sponsored publications and programs. NOF requires disclosure of any significant financial interest or any other relationship that the Conference Planning Committee or Faculty members have with the manufacturer(s) of any commercial product(s) discussed in educational presentations. All faculty and contributors to this continuing medical education activity have disclosed any real or apparent interest that may have direct bearing on the subject matter of this program. Specific disclosure information will be included in the course handout materials.
Click Here to Register Online
Exhibits
Exhibitor List
| Exhibitor |
Booth Number |
| Alliance for Better Bone Health |
500 |
| American Academy of Orthopaedic Surgeons |
419 |
| American Orthopaedic Association |
417 |
| American Society of Bone & Mineral Research |
507 |
| Amgen, Inc. |
400 |
| Eli Lilly and Company |
300 |
| FDA Office of Women’s Health |
418 |
| Hologic, Inc. |
501 |
| International Society for Clinical Densitometry |
518 |
| Lone Oak Medical Technologies |
309 |
| Medtronic |
409 |
| National Association of Nurse Practitioners in Women’s Health |
519 |
| National Osteoporosis Foundation |
315 |
| NIH Osteoporosis and Related Bone Diseases |
510 |
| Novartis Pharmaceuticals |
308 |
| Optasia Medical |
311 |
| Osteoporosis Canada |
218 |
| Roche |
408 |
| Roche Diagnostics |
410 |
| Scanco |
411 |
| United States Bone and Joint Decade |
313 |
Corportate Supporters
Platinum
Amgen
Silver
Eli Lilly
Roche
Bronze
Alliance for Better Bone Health
Friend
Wyeth
Equal Opportunity Statement
The National Osteoporosis Foundation is committed to equal opportunity and nondiscrimination in all programs and services, and does not discriminate on the basis of race/ethnicity, color, religion, sex, including marital status, national origin, ancestry, age, sexual orientation, disability, or veteran status.
Americans with Disabilities Statement
The National Osteoporosis Foundation in support of the spirit of the Americans with Disabilities Act (ADA), endeavors to honor all requests for reasonable accommodations in order for participants and/or members to achieve equal access to all programs and services.
Liability Disclaimer Statement
The National Osteoporosis Foundation shall not be held liable for personal injury, death, property damage or loss suffered by a participant in connection with any program or service, whether due to the negligence of staff or others.
The National Osteoporosis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
|
| |
|